Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Unknown 1Suspended 1Completed 1

Sponsor Class

INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Thoracic 2Gynecologic 2Gastrointestinal 2Dermatologic 2Breast 2Lymphoid 1Head & Neck 1

Conditions

Melanoma 134Carcinoma, Renal Cell 51Kidney Neoplasms 42Leukemia, Myeloid, Acute 38Neoplasm Metastasis 37Leukemia 33Lymphoma 30Breast Neoplasms 26Ovarian Neoplasms 24Lymphoma, Non-Hodgkin 22Carcinoma, Non-Small-Cell Lung 22Skin Neoplasms 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Neuroblastoma 18Lymphoma, Follicular 18Pancreatic Neoplasms 16Lymphoma, Mantle-Cell 16Leukemia, Lymphocytic, Chronic, B-Cell 16Stomach Neoplasms 14Neoplasms 14Myelodysplastic Syndromes 14Colorectal Neoplasms 13Multiple Myeloma 12Lymphoma, Large B-Cell, Diffuse 12Lymphoma, B-Cell, Marginal Zone 12Hodgkin Disease 12Congenital Abnormalities 12Uterine Cervical Neoplasms 11Lymphoma, Large-Cell, Immunoblastic 11Lung Neoplasms 11

Interventions

pembrolizumab 91Gemcitabine 55Nivolumab 49Cisplatin 38atezolizumab 31Carboplatin 30avelumab 25enfortumab vedotin 23Docetaxel 23Magnetic Resonance Spectroscopy 18Ipilimumab 17Paclitaxel 16Mitomycin 15Specimen Handling 14durvalumab 11toripalimab 10sacituzumab govitecan 10Pemetrexed 10cabozantinib 9Taxes 8vinflunine 7Cyclophosphamide 7tislelizumab 6Injections 6Bevacizumab 6pemigatinib 5fludarabine 5disitamab vedotin 5Standard of Care 5Radiosurgery 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Transitional Cell × aldesleukin × Clear all
NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Completed
37 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT03970382 2022-08-18

A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors

PACT Pharma, Inc.

Phase 1 Suspended
21 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Melanoma, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT04383067 2021-02-11

A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients

Sheba Medical Center

Phase 2 Unknown
20 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡